By Josh Beckerman
Shuttle Pharmaceuticals Holdings shares surged after an update related to its Phase 2 clinical trial of ropidoxuridine, a radiation sensitizer for use in combination with radiation therapy to treat brain tumors.
The stock rose 63%, to $2.17, in after-hours trading Monday. As of the market close, shares were down about 63% for the year.
The company said it finalized agreements with all six planned site enrollment locations. Agreements were finalized with Georgetown University Medical Center and UNC Medical Center. It previously reported agreements with four other locations.
Shuttle said in early September that the Phase 2 trial had started enrolling patients with aggressive, IDH wild-type, methylation negative glioblastomas, the company said.
Earlier Monday, Shuttle said Chief Executive Anatoly Dritschilo would present at a ThinkEquity conference Wednesday morning. He will discuss the ropidoxuridine study and provide an update on plans for the Shuttle Diagnostics subsidiary to develop predictive biomarkers for prostate-cancer outcomes following radiation therapy, and novel PSMA ligand for theranostic applications.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
October 28, 2024 18:50 ET (22:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。